Outcomes following infliximab therapy for pediatric patients hospitalized with refractory colitis-predominant IBD

Journal of Pediatric Gastroenterology and Nutrition

Volumn 58, Issue 2, 2014, Pages 213-219

  Falaiye, Tolulope O ^a   Mitchell, Keisha R ^a   Lu, Zengqi ^a   Saville, Benjamin R ^a   Horst, Sara N ^a   Moulton, Dedrick E ^a   Schwartz, David A ^a   Wilson, Keith T ^a   Rosen, Michael J ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

colitis; inflammatory bowel disease; infliximab; inpatient; pediatrics

Indexed keywords

GASTROINTESTINAL AGENT; INFLIXIMAB; MONOCLONAL ANTIBODY; SERUM ALBUMIN;

ADOLESCENT; ADULT; BODY MASS; CHILD; COHORT ANALYSIS; COLITIS, ULCERATIVE; COLON RESECTION; CROHN DISEASE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HOSPITALIZATION; HUMAN; MALE; METABOLISM; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL; BLOOD SEDIMENTATION; BODY MASS INDEX; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; COLECTOMY; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; GASTROINTESTINAL AGENTS; HOSPITALIZATION; HUMANS; INFLIXIMAB; MALE; RETROSPECTIVE STUDIES; SERUM ALBUMIN; SEVERITY OF ILLNESS INDEX; TREATMENT FAILURE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84894087242     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0b013e3182a98df2     Document Type: Article

References (29)

1. Hyams J, Damaraju L, Blank M, et al. Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis. Clin Gastroenterol Hepatol 2012;10:391-9e1.
2. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353:2462-76.
3. Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 2007;132:863-73.
4. Hyams JS, Lerer T, Griffiths A, et al. Outcome following infliximab therapy in children with ulcerative colitis. Am J Gastroenterol 2010; 105:1430-6.
5. Heyman MB, Kirschner BS, Gold BD, et al. Children with early-onset inflammatory bowel disease (IBD): analysis of a pediatric IBD consortium registry. J Pediatr 2005;146:35-40.
6. Gupta N, Bostrom AG, Kirschner BS, et al. Presentation and disease course in early-compared to later-onset pediatric Crohn's disease. Am J Gastroenterol 2008;103:2092-8.
7. Turner D, Mack D, Leleiko N, et al. Severe pediatric ulcerative colitis: a prospective multicenter study of outcomes and predictors of response. Gastroenterology 2010;138:2282-91.
8. Seow CH, Newman A, Irwin SP, et al. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010;59:49-54.
9. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42:377-81.
10. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003;348:601-8.
11. Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012;491:119-24.
12. Hyams JS, Lerer T, Griffiths A, et al. Long-term outcome of maintenance infliximab therapy in children with Crohn's disease. Inflamm Bowel Dis 2009;15:816-22.
13. Wultanska D, Banaszkiewicz A, Radzikowski A, et al. Clostridium difficile infection in Polish pediatric outpatients with inflammatory bowel disease. Eur J Clin Microbiol Infect Dis 2010;29:1265-70.
14. Ordas I, Feagan BG, Sandborn WJ. Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. Clin Gastroenterol Hepatol 2012;10:1079-87quiz e85-6.
15. Maser EA, Villela R, Silverberg MS, et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006;4:1248-54.
16. Fasanmade AA, Adedokun OJ, Olson A, et al. Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis. Int J Clin Pharmacol Ther 2010;48:297-308.
17. Fasanmade AA, Adedokun OJ, Ford J, et al. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur J Clin Pharmacol 2009;65:1211-28.
18. Kelley-Quon LI, Jen HC, Ziring DA, et al. Predictors of proctocolect-omy in children with ulcerative colitis. J Pediatr Gastroenterol Nutr 2012;55:534-40.
19. Grossi V, Lerer T, Markowitz J, et al. Impact of body mass index on efficacy of infliximab in children with inflammatory bowel disease. Gastroenterology 2013;144:S128.
20. Hotamisligil GS, Arner P, Caro JF, et al. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest 1995;95:2409-15.
21. Kern PA, Saghizadeh M, Ong JM, et al. The expression of tumor necrosis factor in human adipose tissue. Regulation by obesity, weight loss, and relationship to lipoprotein lipase. J Clin Invest 1995;95: 2111-9.
22. Hamalainen A, Sipponen T, Kolho KL. Serum infliximab concentrations in pediatric inflammatory bowel disease. Scand J Gastroenterol 2013; 48:35-41.
23. Wolbink GJ, Voskuyl AE, Lems WF, et al. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2005;64:704-7.
24. Sandborn WJ, Hanauer SB. Infliximab in the treatment of Crohn's disease: a user's guide for clinicians. Am J Gastroenterol 2002;97: 2962-72.
25. Sono K, Yamada A, Yoshimatsu Y, et al. Factors associated with the loss of response to infliximab in patients with Crohn's disease. Cytokine 2012;59:410-6.
26. Imaeda H, Andoh A, Fujiyama Y. Development of a new immunoassay for the accurate determination of anti-infliximab antibodies in inflammatory bowel disease. J Gastroenterol 2012;47:136-43.
27. Jurgens M, Mahachie J, Cleynen I, et al. Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease. Clin Gastroenterol Hepatol 2011;9:421-7e1.
28. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362:1383-95.
29. Lichtenstein GR, Diamond RH, Wagner CL, et al. Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials. Aliment Pharmacol Ther 2009;30:210-26.